Ocu-Spore-B Side Effects
Generic name: bacitracin / neomycin / polymyxin b ophthalmic
Medically reviewed by Drugs.com. Last updated on Mar 12, 2024.
Note: This document contains side effect information about bacitracin / neomycin / polymyxin b ophthalmic. Some dosage forms listed on this page may not apply to the brand name Ocu-Spore-B.
Applies to bacitracin/neomycin/polymyxin b ophthalmic: ophthalmic ointment.
Serious side effects of Ocu-Spore-B
Along with its needed effects, bacitracin/neomycin/polymyxin b ophthalmic may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking bacitracin/neomycin/polymyxin b ophthalmic:
More common
- Itching, rash, redness, swelling, or other sign of irritation not present before use of this medicine
After application, eye ointments usually cause your vision to blur for a few minutes.
For Healthcare Professionals
Applies to bacitracin / neomycin / polymyxin b ophthalmic: ophthalmic ointment.
Hypersensitivity
Frequency not reported: Allergic sensitization reactions (including itching, swelling, conjunctival erythema), more serious hypersensitivity reactions (including anaphylaxis)[Ref]
Local
Frequency not reported: Local irritation upon administration[Ref]
Frequently asked questions
More about Ocu-Spore-B (bacitracin / neomycin / polymyxin b ophthalmic)
- Compare alternatives
- Latest FDA alerts (1)
- Dosage information
- During pregnancy
- Drug class: ophthalmic anti-infectives
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
References
1. (2022) "Product Information. Neosporin Ophthalmic (gramicidin/neomycin/polymyxin B ophthalmic)." Monarch Pharmaceuticals Inc
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.